[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655776":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":11,"studyPopulation":11,"armGroups":46,"interventions":59,"overallOfficials":11,"centralContacts":69,"locations":75,"responsibleParty":93,"collaborators":11,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":11,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":102,"minAge":103,"maxAge":11,"enrollmentInfo":104,"targetDuration":11,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":11,"overallStatus":78,"whyStopped":11,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Alexandria University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change of Hemoglobin Concentration",null,"From baseline (preoperative) up to hospital discharge (typically 3-5 days postoperatively).",[14,18,21,25,29,33],{"measure":15,"description":16,"timeFrame":17},"Postoperative Calculated Blood Loss","Volume of total blood loss calculated as a function of patient characteristics (sex, height, weight) and perioperative hemoglobin balance using standard Gross and Nadler mathematical formulas.","From day 1 Up to hospital discharge.",{"measure":19,"description":20,"timeFrame":17},"Postoperative Calculated Hemoglobin Loss","Total mass of hemoglobin loss calculated based on patient baseline physical parameters and perioperative hemoglobin balance.",{"measure":22,"description":23,"timeFrame":24},"Number of Blood Units Transfused","The total cumulative units of blood products administered per patient.","From the start of surgery at day 1 up to hospital discharge.",{"measure":26,"description":27,"timeFrame":28},"Blood Transfusion Rate","The percentage\u002Fproportion of patients requiring allogeneic blood transfusion.","From day 1 at the start of surgery up to hospital discharge",{"measure":30,"description":31,"timeFrame":32},"Length of Hospital Stay","Total number of days from surgical admission to official hospital discharge","Up to 30 days postoperatively.",{"measure":34,"description":35,"timeFrame":32},"Incidence of Thromboembolic Events","Frequency of clinical or diagnostic thromboembolic complications (including deep venous thrombosis, pulmonary embolism, myocardial infarction, or stroke",{"allocation":37,"interventionModel":38,"interventionModelDescription":11,"primaryPurpose":39,"observationalModel":11,"timePerspective":11,"maskingInfo":40},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":41,"maskingDescription":11,"whoMasked":42},"TRIPLE",[43,44,45],"PARTICIPANT","CARE_PROVIDER","OUTCOMES_ASSESSOR",[47,53],{"label":48,"type":49,"description":50,"interventionNames":51},"Intramuscular TXA","EXPERIMENTAL","Tranexamic acid 1 gram administered via deep intramuscular injection into the lateral thigh or deltoid muscle prior to surgery. Anesthesia maintained with a balanced inhalational technique (isoflurane 1-1.5% in oxygen-enriched air) and baseline fluid therapy 10 ml per kg per hour of lactated Ringer's solution).",[52],"Drug: Tranexamic Acid (TXA) intarmuscular",{"label":54,"type":55,"description":56,"interventionNames":57},"Intravenous TXA","ACTIVE_COMPARATOR","Tranexamic acid 1 gram administered intravenously over 10 minutes, following standard protocols, prior to surgery. Anesthesia maintained with a balanced inhalational technique (isoflurane 1-1.5% in oxygen-enriched air) and baseline fluid therapy 10 ml per kg per hour of lactated Ringer's solution).",[58],"Drug: Tranexamic Acid (TXA) intravenous",[60,65],{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":11},"DRUG","Tranexamic Acid (TXA) intarmuscular","Tranexamic acid 1 gram administered via deep intramuscular injection into the lateral thigh or deltoid muscle prior to surgery.",[48],{"type":61,"name":66,"description":67,"armGroupLabels":68,"otherNames":11},"Tranexamic Acid (TXA) intravenous","Tranexamic acid 1 gram administered intravenously over 10 minutes, following standard protocols, prior to surgery.",[54],[70],{"name":71,"role":72,"phone":73,"phoneExt":11,"email":74},"Tarek I Ismail","CONTACT","+201001467166","Drtarek.anesth@gmail.com",[76],{"facility":77,"status":78,"city":79,"state":11,"zip":11,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":87,"contacts":88},"Alexandria university main hospitals","RECRUITING","Alexandria","Egypt","EG",{"type":83,"coordinates":84},"Point",[85,86],29.91582,31.20176,{"lat":86,"lon":85},[89],{"name":90,"role":72,"phone":91,"phoneExt":11,"email":92},"Rabab S Saber","+201223479339","Rabab.saleh@alexmed.edu.eg",{"type":94,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100655776","early-phase-1-evaluating-the-effectiveness-of-intramuscular-versus-intravenous-tranexamic-acid-for-minimizing-blood-loss-after-total-hip-arthroplasty-a-randomized-controlled-trial-100655776",false,"NCT07817537","Evaluating the Effectiveness of Intramuscular Versus Intravenous Tranexamic Acid for Minimizing Blood Loss After Total Hip Arthroplasty: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Adult patients aged 18 years and older.\n2. Scheduled to undergo elective primary total hip arthroplasty.\n3. Able to provide informed consent.\n\nExclusion Criteria:\n\n* 1\\. History of renal failure or kidney transplant. 2. History of an arterial thromboembolic event (such as myocardial infarction or stroke) within the past year.\n\n  3\\. Placement of an arterial stent within the past year. 4. History of deep venous thrombosis (DVT) or pulmonary embolism (PE). 5. Known contraindications to tranexamic acid. 6. Pregnancy or breastfeeding. 7. Refusal to participate or refusal to consent to receive blood products.",true,"ALL","18 Years",{"count":105,"type":106},128,"ESTIMATED","INTERVENTIONAL",[109],"EARLY_PHASE1","Intramuscular vs. Intravenous Tranexamic Acid for Total Hip Arthroplasty",[112],"Blood Loss After a Total Hip Replacement","2026-09-07",{"date":115,"type":116},"2026-09-14","ACTUAL",{"date":118,"type":116},"2026-01-15",{"date":120,"type":106},"2027-03-01",{"name":5,"class":6},1]